Impact of post-procedural glycemic variability on cardiovascular morbidity and mortality after transcatheter aortic valve implantation: a post hoc cohort analysis.
Adverse events
Aortic disease
Blood glucose
Glucose variability
Transcatheter aortic valve implantation
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
11 03 2019
11 03 2019
Historique:
received:
16
11
2018
accepted:
19
02
2019
entrez:
13
3
2019
pubmed:
13
3
2019
medline:
24
4
2019
Statut:
epublish
Résumé
Glycemic variability is associated with worse outcomes after cardiac surgery, but the prognosis value of early glycemic variability after transcatheter aortic valve implantation is not known. This study was therefore designed to analyze the prognosis significance of post-procedural glycemic variability within 30 days after transcatheter aortic valve implantation. A post hoc analysis of patients from our center included in the FRANCE and FRANCE-2 registries was conducted. Post-procedural glycemic variability was assessed by calculating the mean daily δ blood glucose during the first 2 days after transcatheter aortic valve implantation. Major complications within 30 days were death, stroke, myocardial infarction, acute heart failure, and life-threatening cardiac arrhythmias. We analyzed 160 patients (age (median [interquartile] = 84 [80-88] years; diabetes mellitus (n) = 41 (26%) patients; logistic Euroscore = 20 [12-32]). The median value of mean daily δ blood glucose was 4.3 mmol l This study showed that post-procedural glycemic variability was associated with an increased risk of major complications within 30 days after transcatheter aortic valve implantation. Trial registration Clinical trial registration number https://www.clinicaltrials.gov/ ; identifier: NCT02726958; date: April 4th, 2016.
Sections du résumé
BACKGROUND
Glycemic variability is associated with worse outcomes after cardiac surgery, but the prognosis value of early glycemic variability after transcatheter aortic valve implantation is not known. This study was therefore designed to analyze the prognosis significance of post-procedural glycemic variability within 30 days after transcatheter aortic valve implantation.
METHODS
A post hoc analysis of patients from our center included in the FRANCE and FRANCE-2 registries was conducted. Post-procedural glycemic variability was assessed by calculating the mean daily δ blood glucose during the first 2 days after transcatheter aortic valve implantation. Major complications within 30 days were death, stroke, myocardial infarction, acute heart failure, and life-threatening cardiac arrhythmias.
RESULTS
We analyzed 160 patients (age (median [interquartile] = 84 [80-88] years; diabetes mellitus (n) = 41 (26%) patients; logistic Euroscore = 20 [12-32]). The median value of mean daily δ blood glucose was 4.3 mmol l
CONCLUSIONS
This study showed that post-procedural glycemic variability was associated with an increased risk of major complications within 30 days after transcatheter aortic valve implantation. Trial registration Clinical trial registration number https://www.clinicaltrials.gov/ ; identifier: NCT02726958; date: April 4th, 2016.
Identifiants
pubmed: 30857532
doi: 10.1186/s12933-019-0831-3
pii: 10.1186/s12933-019-0831-3
pmc: PMC6410509
doi:
Substances chimiques
Biomarkers
0
Blood Glucose
0
Banques de données
ClinicalTrials.gov
['NCT02726958']
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
27Références
Diabetes Care. 2004 Feb;27(2):461-7
pubmed: 14747229
Crit Care. 2004 Jun;8(3):R122-7
pubmed: 15153239
JAMA. 2006 Apr 12;295(14):1681-7
pubmed: 16609090
Anesthesiology. 2006 Aug;105(2):244-52
pubmed: 16871057
Crit Care. 2008;12(1):R24
pubmed: 18302732
Crit Care Med. 2008 Aug;36(8):2316-21
pubmed: 18596625
Crit Care Med. 2008 Nov;36(11):3008-13
pubmed: 18824908
Crit Care Med. 2010 Apr;38(4):1021-9
pubmed: 20124887
Eur J Cardiothorac Surg. 2010 Aug;38(2):119-27
pubmed: 20206542
Diabet Med. 2010 Aug;27(8):968
pubmed: 20653758
Eur Heart J. 2011 Jan;32(2):191-7
pubmed: 20843959
N Engl J Med. 2010 Oct 21;363(17):1597-607
pubmed: 20961243
N Engl J Med. 2012 May 3;366(18):1705-15
pubmed: 22551129
N Engl J Med. 2012 Sep 20;367(12):1108-18
pubmed: 22992074
Eur Heart J. 2012 Oct;33(19):2403-18
pubmed: 23026477
Anesth Analg. 2014 Feb;118(2):277-87
pubmed: 24445629
N Engl J Med. 2014 Sep 4;371(10):967-8
pubmed: 25184874
Eur J Cardiothorac Surg. 2016 Feb;49(2):420-6
pubmed: 25825261
Ann Intensive Care. 2015 Dec;5(1):34
pubmed: 26525053
J Diabetes Complications. 2016 May-Jun;30(4):613-7
pubmed: 26965795
Am J Cardiol. 2016 May 15;117(10):1636-1642
pubmed: 27015888
Int J Cardiol. 2016 Oct 15;221:892-7
pubmed: 27434367
Eur J Cardiothorac Surg. 2017 Jan;51(1):80-88
pubmed: 27582074
Am J Cardiol. 2016 Oct 1;118(7):1031-45
pubmed: 27634034
Am J Cardiol. 2016 Dec 1;118(11):1692-1697
pubmed: 27666174
Clin Kidney J. 2013 Feb;6(1):8-14
pubmed: 27818745
Anesth Analg. 2017 Jan;124(1):16-22
pubmed: 27861432
Am J Cardiol. 2017 Feb 15;119(4):623-629
pubmed: 27931726
Int J Cardiol. 2017 Jun 1;236:350-355
pubmed: 28111053
Interact Cardiovasc Thorac Surg. 2018 Mar 1;26(3):413-419
pubmed: 29088475
Cardiovasc Diabetol. 2017 Nov 09;16(1):144
pubmed: 29121921
Cardiovasc Diabetol. 2018 Feb 24;17(1):33
pubmed: 29477146
Cardiovasc Diabetol. 2018 Mar 7;17(1):36
pubmed: 29514695
Diabetes Care. 2018 Oct;41(10):2187-2194
pubmed: 30082325
Cardiovasc Diabetol. 2018 Aug 18;17(1):116
pubmed: 30121076
Diabetes Metab Syndr. 2019 Jan - Feb;13(1):149-153
pubmed: 30641688